<!DOCTYPE html>
<html>

<script>
location.replace("https://www.braincommons.org/publications/doi-10-1016-j-cytox-2020-100027/")
</script>
    
<head>
    <meta http-equiv='Content-Type' content='text/html; charset=UTF-8'>
    <link rel='stylesheet' type='text/css' href='index.css' />
    <link rel='icon' href='img/favicon.ico' type='image/x-icon' />
    <title>Publications</title>
</head>

<body>
    <div id="root">
        <div class='top-bar'>
            <div class='top-bar__header'>
            </div>
        </div>
        <div class='nav-bar'>
            <div class='nav-bar__header'>
                <div class='nav-bar__logo'>
                    <img src='img/header-logo.png' class='nav-bar__logo-img' />
                </div>
            </div>
        </div>
        <div class='main-content'>
            <div class='publication-info'>
                <h1>Cross-platform Comparison of Highly Sensitive Immunoassay Technologies for Cytokine Markers:
                    Platform Performance in Post-traumatic Stress Disorder and Parkinson's Disease</h1>
                <h2>
                    <span style="color: blue;">Publications:</span><a
                        href="https://doi.org/10.1016/j.cytox.2020.100027"> Cross-platform Comparison of
                        Highly Sensitive Immunoassay Technologies for Cytokine Markers: Platform Performance in
                        Post-traumatic Stress Disorder and Parkinson's Disease</a>
                </h2>
                <h2>
                    <span style="color: red; font-style: italic;">Cytokine X. </span><span style="color: red;">Volume 2,
                        Issue 2, June 2020; DOI link: <a style="color: red;"
                            href="https://doi.org/10.1016/j.cytox.2020.100027">https://doi.org/10.1016/j.cytox.2020.100027</a></span>
                </h2>
                <p style="text-align: justify; line-height: 1.5;">
                    <span style="font-weight: bold;">Authors: </span><span>Heather C. Lasseter, Allison C. Provost,
                        Lauren E. Chaby, Nikolaos P. Daskalakis, Magali Haas, Andreas Jeromin</span>
                </p>
                <p style="text-align: justify; line-height: 1.5;"> <span style="font-weight: bold;">Abstract:</span>
                    There is mounting evidence of systemic inflammation in post-traumatic stress disorder (PTSD) and
                    Parkinson&rsquo;s disease (PD), yet inconsistency and a lack of replicability in findings of
                    putative biological markers have delayed progress in this space. Variability in performance between
                    platforms may contribute to the lack of consensus in the biomarker literature, as has been seen for
                    a number of psychiatric disorders, including PTSD. Thus, there is a need for high-performance,
                    scalable, and validated platforms for the discovery and development of biomarkers of inflammation
                    for use in drug development and as clinical diagnostics. To identify the best platform for use in
                    future biomarker discovery efforts, we conducted a comprehensive cross-platform and cross-assay
                    evaluation across five leading platform technologies. This initial assessment focused on four
                    cytokines that have been implicated PTSD &ndash; interleukin (IL)-1&beta;, IL-6, tumor necrosis
                    factor (TNF)-&alpha;, and interferon (IFN)-&gamma;<span id="dots">&nbsp;...</span><span id="more">.
                        To assess platform performance and understand likely
                        measurements in individuals with brain disorders, serum and plasma samples were obtained from
                        individuals with PTSD (n = 13) or Parkinson&rsquo;s Disease (n = 14) as well as healthy controls
                        (n = 5). We compared platform performance across a number of common analytic parameters,
                        including assay precision, sensitivity, frequency of endogenous analyte detection (FEAD),
                        correlation between platforms, and parallelism in measurement of cytokines using a serial
                        dilution series. The single molecule array (Simoa&trade;) ultra-sensitive platform (Quanterix),
                        MESO V-Plex (Mesoscale Discovery), and Luminex xMAP&reg; (Myriad) were conducted by their
                        respective vendors, while Luminex&reg; and Quantikine&reg; high-sensitivity ELISA assays were
                        evaluated by R&amp;D System&rsquo;s Biomarker Testing Services. The assay with the highest
                        sensitivity in detecting endogenous analytes across all analytes and clinical populations (i.e.
                        the highest FEAD), was the Simoa&trade; platform. In contrast, more variable performance was
                        observed for MESO V-plex, R&amp;D Luminex&reg; and Quantikine&reg;, while Myriad&rsquo;s Luminex
                        xMAP&reg; exhibited low FEAD across all analytes and samples. Simoa&trade; also demonstrated
                        high precision in detecting endogenous cytokines, as reflected in &lt; 20 percent coefficient of
                        variance (%CV) across replicate runs for samples from the healthy controls, PTSD patients, and
                        PD
                        patients. In contrast, MESO V-Plex, R&amp;D Luminex&reg; and Quantikine&reg; had variable
                        performance in terms of precision across cytokines. Myriad Luminex xMAP&reg; could not be
                        included in precision estimates because the vendor did not run samples in duplicate. For
                        cross-platform performance comparisons, the highest cross-platform correlations were observed
                        for IL-6 such that all platforms &ndash; except for Myriad&rsquo;s Luminex xMAP&reg; &ndash; had
                        strong correlations with one another in measurements of IL-6 (r range = 0.59 &ndash; 0.86). For
                        the other cytokines, there was low to no correlation across platforms, such that reported
                        measurements of IL-1&beta;, TNF-&alpha;, and IFN-&gamma; varied across assays. Taken together,
                        these findings provide novel evidence that the choice of immunoassay could greatly impact
                        reported cytokine findings. The current study provides crucial information on the variability in
                        performance between platforms and across immunoassays that may help inform the selection of
                        assay in future research studies. Further, the results emphasize the need for performing
                        comparative evaluations of immunoassays as new technologies emerge over time, particularly given
                        the lack of reference standards for the quantitative assessments of cytokines.</span>
                    <button onclick="readMore()" id="read-more-btn">Read more</button>
                </p>
            </div>
            <div class='other-info'>
                <h2 class="section-title">Data in the BRAIN Commons</h2>
                <p>The dataset for this project is hosted in the BRAIN Commons, the cloud based platform for
                    computational discovery designed for the brain health community.</p>
                <p>For more information about the BRAIN Commons, visit <a
                        href="https://www.braincommons.org">https://www.braincommons.org</a></p>
                <h2 class="section-title">Instructions for Data Download</h2>
                <div id="list-wrapper">
                    <ol>
                        <li>
                            <p>Go to <a href="">this
                                    link</a> to obtain the data file from BRAIN Commons.</p>
                        </li>
                        <li>
                            <p>If prompted, login with your credentials.</p>
                        </li>
                        <li>
                            <p>Click on the <span style="color:chocolate;">"Download"</span> button from the data file
                                page. Your download should start momentarily.</p>
                        </li>
                        <li>
                            <p>Additional data will be made available to a qualified researcher community in the future.
                            </p>
                        </li>
                    </ol>
                </div>
                <h2 class="section-title">Acknowledgements and Funding</h2>
                <p style="text-align: justify; line-height: 1.5;">This work was supported primarily by Cohen Veterans
                    Bioscience and generous grants COH-0013 and COH-0003 from Steven A. Cohen for the RAPID-Dx (<a
                        href="https://www.cohenveteransbioscience.org/programs/our-programs/rapid-dx/">Research Alliance
                        for PTSD/TBI Innovation and Discovery
                        Diagnostics</a>) program. Additional funding was provided by the Michael J. Fox Foundation
                    (MJFF). Cohen Veterans Bioscience would also like to acknowledge the MJFF for use of Parkinson's
                    disease samples. Parkinson's disease data used in the preparation of this article were obtained from
                    the MJFF-sponsored
                    LRRK2 Cohort Consortium (LCC). For up-to-date information on the study, visit <a
                        href="http://www.michaeljfox.org/lcc">http://www.michaeljfox.org/lcc</a>.
                    The LRRK2 Cohort Consortium is coordinated and funded by The Michael J. Fox Foundation for
                    Parkinson's Research. In addition, PTSD biospecimens were donated from the longitudinal cohort study
                    of the Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation
                    Research and Development Traumatic Brain Injury Center of Excellence (B3001-C).</p>
                <p>Moreover, we are immensely grateful to the Indiana University Genetic Biobank for their expertise in
                    the processing and plating of all samples as well as the technology vendors for participating in
                    this cross-platform comparison and providing their technical expertise in processing immunoassays.
                </p>
                <p>HCL, ACP, LC, NPD, MH, and AJ are employed by Cohen Veterans Bioscience Inc., a nonprofit 501(c)(3)
                    research organization. The authors report no biomedical financial interests or potential
                    conflicts of interest.</p>
                <h2 class="section-title">Declaration of Competing Interest</h2>
                <p>AJ has been an advisor to Quanterix, Inc and holds stock options. The other authors (HCL, ACP, LC,
                    NPD, and MH) declare that they have
                    no known competing financial interests or personal relationships that could have appeared to
                    influence the work reported in this paper.</p>
                <h2 class="section-title">About Cohen Veteranâ€™s Bioscience</h2>
                <p style="text-align: justify; line-height: 1.5;">Cohen Veterans Bioscience is a nonprofit 501(c)(3)
                    research organization dedicated to fast-tracking
                    the development of diagnostic tests and personalized therapeutics for the millions of veterans and
                    civilians who suffer the devastating effects of trauma-related and other brain disorders. <a
                        href="https://www.cohenveteransbioscience.org/">Learn More
                        at CohenVeteransBioscience.org</a></p>
            </div>
        </div>
        <div class='footer'>
            <div class="footer__logo-area">
                <img class='footer__img' src='img/gen3.png' />
                <img class='footer__img' src='img/createdby.png' />
            </div>
        </div>
    </div>

    <script>
        function readMore() {
            var dots = document.getElementById("dots");
            var moreText = document.getElementById("more");
            var btnText = document.getElementById("read-more-btn");

            if (dots.style.display === "none") {
                dots.style.display = "inline";
                btnText.innerHTML = "Read more";
                moreText.style.display = "none";
            } else {
                dots.style.display = "none";
                btnText.innerHTML = "Read less";
                moreText.style.display = "inline";
            }
        }
    </script>

</body>

</html>
